StockNews.com Upgrades Sanofi (NASDAQ:SNY) to Strong-Buy

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research report report published on Friday.

Several other research analysts have also weighed in on SNY. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the company a buy rating in a research report on Friday, July 26th. Citigroup raised Sanofi to a strong-buy rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of Moderate Buy and a consensus target price of $57.50.

Sanofi Trading Down 1.1 %

Shares of NASDAQ SNY opened at $57.63 on Friday. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $54.34 and a 200-day simple moving average of $50.50.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 earnings per share. Sell-side analysts predict that Sanofi will post 4.25 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SNY. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the 2nd quarter valued at about $25,000. Frazier Financial Advisors LLC bought a new stake in Sanofi during the 4th quarter valued at approximately $28,000. Register Financial Advisors LLC bought a new stake in Sanofi during the 1st quarter valued at approximately $29,000. Larson Financial Group LLC boosted its stake in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in Sanofi during the 4th quarter valued at approximately $31,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.